The Danish eye-screening software manufacturer, RetinaLyze System A/S (Ltd.), a market leader in retinal screening software, is introducing another new and accessible eye-screening service; an artificial intelligence-based screening service designed to detect glaucoma called RetinaLyze Glaucoma.
“This new service will revolutionise how eye-screening for glaucoma
is performed and also change who can perform them. We are, and always have
been, committed to make eye-screenings
accessible for the general public and providing our customers with easy,
efficient and fast solutions for performing eye-screening for eye-diseases,”
says Ganesh Ram, CCO of RetinaLyze System A/S (Ltd.).
Glaucoma is the leading cause of irreversible blindness in the world. In 2013, the number of people with glaucoma worldwide
was estimated to be 64,3 million, increasing 76 million in 2020 and to 111,8 million in 2040.[1]
While there are no known cures for glaucoma, blindness or significant vision loss from glaucoma can be prevented if the disease is recognized in the early stages. In its most prevalent form—primary open angle glaucoma—vision loss is silent, slow, and progressive. It typically affects side vision first (peripheral vision) and as it progresses, central vision is lost.
Currently, regular eye exams are the best form of prevention against significant glaucoma damage. The earlier the condition is discovered, the easier and cheaper it is to stop the disease from developing.
RetinaLyze System aims to make eye-screenings accessible for the general public. To make this happen, RetinaLyze System’s services lower the cost of each screening and reduce the price and complexity of the equipment necessary to perform eye-screenings. The new RetinaLyze Glaucoma algorithm furthermore makes it possible for eye-specialists, such as ophthalmologists, optometrists and nurses, to perform glaucoma screenings efficiently and safely. RetinaLyze Glaucoma analyzes retinal images automatically. It can assess the risk of having glaucoma and gives a result instantly. The entire process involves only the image from fundus cameras – no visual field analyzer or tonometer is necessary.
RetinaLyze Glaucoma assesses the level of hemoglobin in the Optic Disc, which can be used as a measurement of damage to the Optic Nerve Head, and calculates the risk of having signs of Glaucoma. The algorithm uses only fundus images as input, but achieves similar performance as visual perimetry and OCT screening methods.
RetinaLyze Glaucoma is a new algorithm, which is a part of the RetinaLyze web application. The RetinaLyze web application offers easy-to-use automated analysis of retinal images for signs of Diabetic Retinopathy, AMD and Glaucoma as well as a built-in telemedicine solution.
The ease-of-use, as well as the simplicity of the eye exam and the speed of the result, makes the RetinaLyze service an ideal eye-screening tool for clinics and optometry practices of all sizes.
RetinaLyze System will begin delivering the RetinaLyze Glaucoma service to customers on the 1st of May 2018. More information will follow in the coming days and weeks.
RetinaLyze System A/S is a medical technology company established in 2013, which is represented in 35 countries all over the world. The company delivers groundbreaking decision support tools to eye-screening professionals to enable efficient, accessible and fast eye-screenings. All our algorithms and services are CE-marked, clinically validated and patented.
Lasse Bundgaard
Head of Global Sales
Tel. +45 42 70 12 03
Email: lbu@retinalyze.com
Ganesh Ram
Chief Commercial Officer
Tel. +45 25 94 44 08
Email: gr@retinalyze.com
[1]http://www.aaojournal.org/article/S0161-6420(14)00433-3/abstract
